Evidence map›Paper›PMID 37744426›Full record

ArticleClinical Medicine Insights. Oncology2023

Comparing Tribbles Homolog 3 (TRIB3) Protein Expression Levels with Clinicopathological Characteristics and Survival Among Neuroblastoma Patients.

Burçin Baran, Gamze Sanlav, Deniz Kızmazoğlu, Selen Kum Özşengezer, Safiye Aktaş, Zekiye Altun, Nur Olgun

Abstract read
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Burçin BaranDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylül University, Izmir, Turkey.ORCID https://orcid.org/0000-0002-0917-5443
Gamze SanlavDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylül University, Izmir, Turkey.
Deniz KızmazoğluDepartment of Pediatric Oncology, Institute of Oncology, Dokuz Eylül University, Izmir, Turkey.
Selen Kum ÖzşengezerDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylül University, Izmir, Turkey.
Safiye AktaşDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylül University, Izmir, Turkey.
Zekiye AltunDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylül University, Izmir, Turkey.
Nur OlgunDepartment of Pediatric Oncology, Institute of Oncology, Dokuz Eylül University, Izmir, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tribbles Homolog 3 (TRIB3) is a member of the pseudokinase family of tribbles and acts as an adaptor protein to regulate different cellular processes. Upregulation of TRIB3 expression was shown either as a favorable or an adverse prognostic factor in various adult malignancies. However, TRIB3 expression has not been examined in pediatric cancers. Neuroblastoma is the most common malignant solid tumor of childhood, which affects mostly children under 5 years old. Risk stratification of patients defined by International Neuroblastoma Risk Group was used to determine prognosis and treatment of the disease. This study aimed to examine the relationship between TRIB3 protein expression levels and clinicopathological features and survival of patients. Methods: TRIB3 protein expression was analyzed using immunohistochemical staining on formalin-fixed paraffin-embedded tissue samples of neuroblastoma patients (n = 56). Survival analyses were performed with Kaplan-Meier method and log-rank tests. Association between TRIB3 expression and clinicopathological characteristics were analyzed with Spearman's correlation. Results: Of the patients, 32.1% were in the low-risk group, 21.4% in the medium-risk group, and 46.4% in the high-risk group. Survival analysis was performed in the entire neuroblastoma patient group and sub-risk groups of neuroblastoma patients. In the entire patient group, there was no significant difference in overall survival ( Conclusion: TRIB3 expression is a potential predictive biomarker for low-risk neuroblastoma patients.

Indexed as

biomarkerNeuroblastomaprognosissurvivalTRIB3

Identifiers

PMID37744426
PMCPMC10515557

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.